None listed
Conditions
Interventions
Medical Device : Eligible subjects will be randomized with a 1:1 ratio either of DCS group or DES group. For percutaneous coronary intervention, the Polymer-free drug-coated stent (BioFreedom Ultra st
Sponsors
Yonsei University Health System, Severance Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age =19 years 2. All subjects who are acceptable candidates for treatment with a DCS or DES because of ACS 3. Provision of informed consent
Exclusion criteria
Exclusion criteria: 1. Current or potential pregnancy 2. Need of oral anticoagulation therapy 3. Inability to follow the patient over the period of 1 year after enrollment, as assessed by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patient-oriented composite endpoint (POCE): The composite of all-cause death, MI, or any revascularization | — |
Secondary
| Measure | Time frame |
|---|---|
| Device-oriented composite endpoint (DOCE): The composite of cardiovascular death, MI (not clearly attributable to a non-target vessel), or clinically-driven target-lesion revascularization (TLR);All-cause death;Cardiovascular death;Myocardial infarction;Stroke;Stent thrombosis (definite or probable);Any revascularization;Target-vessel revascularization;Non-target vessel revascularization;Target-lesion revascularization;BARC type 2-5 bleeding;BARC type 3-5 bleeding | — |
Countries
Korea, Republic of
Contacts
Public ContactChul-Min Ahn
Yonsei University Health System, Severance Hospital
Outcome results
None listed